GlassScriptPhysician profile
David L Barnes
NPI 1124081211
$10,591.19
in general payments reported to CMS, 2019-2025
44 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $1,262 · 2021: $2,075 · 2022: $1,533 · 2023: $1,620 · 2024: $1,121 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,784 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,783.56 |
| Education | $114.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,155.38 | 2019-2025 | Vraylar, Ubrelvy, Rinvoq |
| Astrazeneca Pharmaceuticals LP | $1,712.96 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $788.81 | 2019-2025 | Taltz, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $546.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $518.68 | 2019-2025 | |
| Novo Nordisk INC | $496.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $394.91 | 2019-2025 | Repatha, Evenity, Enbrel |
| Allergan, INC. | $336.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.24 | 2019-2023 | Trintellix, Gattex |
| Astellas Pharma US INC | $284.01 | 2019-2023 | Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $272.79 | 2019-2023 | Austedo |
| Sanofi-Aventis U.S. LLC | $261.52 | 2019-2023 | |
| Pfizer INC. | $241.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.32 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $198.90 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.